ライフサイエンスコーパス: hair loss

1 alp including androgenetic alopecia (pattern hair loss).

2 um of the hair follicle and induce alopecia (hair loss).

3 nner fibers and can result in female-pattern hair loss.

4 ty, hyperkeratosis, scaling, skin folds, and hair loss.

5 ndant skin, papillomas, shortened nails, and hair loss.

6 volvement of the innate immune system in the hair loss.

7 er root sheath resulted in subsequent severe hair loss.

8 nt and cycling, eventually leading to severe hair loss.

9 nvolved either directly or indirectly in the hair loss.

10 petitive hair pulling that causes noticeable hair loss.

11 minoxidil is effective at retarding further hair loss.

12 ng the 1 mg/day preparation for male-pattern hair loss.

13 dulating inflammatory response in autoimmune hair loss.

14 TRA treatment, including skin irritation and hair loss.

15 developed fewer papillomas and had systemic hair loss.

16 SA in men aged 40-60 years with male-pattern hair loss.

17 engineer hair follicles for the treatment of hair loss.

18 appear malnourished, and exhibit progressive hair loss.

19 kine production in the development of patchy hair loss.

20 be useful to prevent chemotherapy-associated hair loss.

21 probably very rare, between vaccinations and hair loss.

22 as recombinant Shh protein partially rescued hair loss.

23 ctivate hair growth in animals with complete hair loss.

24 scalp causing keloid-like scar formation and hair loss.

25 ne-mediated disorder that causes nonscarring hair loss.

26 A) is an autoimmune disease characterized by hair loss.

27 adequately classified the severity of scalp hair loss.

28 ogical activation of SHH rescued HFD-induced hair loss.

29 brotic processes, often leading to permanent hair loss.

30 ease causing highly morbid inflamed skin and hair loss.

31 chitecture, leading to bulge destruction and hair loss.

32 tar and periorificial keratoderma, itch, and hair loss.

33 AA) is one of the most common forms of human hair loss.

34 rations of hair shape and length followed by hair loss.

35 l pyruvate carrier (MPC) inhibitors to treat hair loss.

36 ent 24 weeks for scalp, eyebrow, and eyelash hair loss.

37 ith symptoms ranging from chronic fatigue to hair loss.

38 pecia associated with progressive, permanent hair loss.

39 t complex trait distinct from female pattern hair loss.

40 y be a promising target for the treatment of hair loss.

41 these treatments with patients experiencing hair loss.

42 and 0.804 with respect to log of percentage hair loss.

43 nutritional supplements in the treatment of hair loss.

44 g hair follicle miniaturization and eventual hair loss.

45 of hair follicle stem cells, culminating in hair loss.

46 llent in vivo model for chemotherapy-induced hair loss.

47 ed wearing a wig or hat because of extensive hair loss.

48 a is an immune-mediated, nonscarring form of hair loss.

49 receptor signaling in mediating DXR-induced hair loss.

50 s for the management of chemotherapy-induced hair loss.

51 sis in hair matrix keratinocytes followed by hair loss.

52 d here suggest novel approaches to reversing hair loss.

53 minosis A from inadequate vitA intake causes hair loss.

54 In humans, excess RA is associated with hair loss.

55 hair differentiation and cycling, leading to hair loss.

56 and chest/abdomen (38.1% v 9.1%), as well as hair loss (14.0% v 6.3%).

57 neutrophil and eosinophil infiltrates but no hair loss (15 of 15).

58 ed taste/olfaction (16% vs 6%, P < .001) and hair loss (17% vs 10%, P = .004) were more common.

59 ), headache (44%), attention disorder (27%), hair loss (25%), and dyspnea (24%).

60 re for anosmia (aHR 6.49, 95% CI 5.02-8.39), hair loss (3.99, 3.63-4.39), sneezing (2.77, 1.40-5.50),

61 significantly lower than in normals without hair loss (59.5 [40.8, 78.1]).

62 tosis in the hair follicle (HF) resulting in hair loss, a common side effect of cancer therapy.

63 ng of a new recessive mouse mutation causing hair loss, a new wavy-coated phenotype appeared.

64 provide a way to standardize measurements of hair loss across a range of conditions.

65 described inflammatory and scarring type of hair loss affecting almost exclusively women.

66 hia is a rare, recessively inherited form of hair loss affecting both males and females and is charac

67 Hair loss affects millions globally, significantly impac

68 nificantly more likely to have less than 50% hair loss after the fourth chemotherapy cycle compared w

69 tions included 16 with positive rechallenge (hair loss after vaccination on more than 1 occasion), 4

70 Chemotherapy-induced hair loss (alopecia) (CIA) remains a major unsolved prob

71 red memory (RR 2.53; 95% CI 1.82, 3.52), and hair loss/alopecia (RR 2.38; 95% CI 1.69, 3.33).

72 Having noted increasing hair loss among our patients treated with voriconazole,

73 system is associated with a lower amount of hair loss among women receiving specific chemotherapy re

74 o create 2 additional versions, 1 with scalp hair loss and 1 with complete hair loss, for a total of

75 on in families who show an inherited form of hair loss and a hair growth defect.

76 with more wrinkling, whereas female pattern hair loss and a higher free androgen index were associat

77 using cameras because it results in visible hair loss and affects a broad host range.

78 r and clinician-reported outcome for eyebrow hair loss and eyelash hair loss scores of 0 or 1 (full c

79 aged mice (12 months), PTEN deletion induced hair loss and facial hyperplasia of the epidermis.

80 proliferation of basal layer cells, leads to hair loss and impairs regeneration after wounding.

81 with mild dryness of the tail accompanied by hair loss and inflammation at the base of the tail.

82 re, we show that acute stress triggers rapid hair loss and initiates autoimmunity.

83 hese findings suggest treatments for wounds, hair loss and other degenerative skin disorders.

84 ovide potential targets for the treatment of hair loss and other disorders of skin and hair.

85 opportunities for developing treatments for hair loss and other skin disorders.

86 itor 2-difluoromethylornithine could prevent hair loss and partially normalize skin histology if admi

87 ata (AA) is an autoimmune disease defined by hair loss and peribulbar infiltrate of CD8 and CD4 T cel

88 erozygous mice are characterized by repeated hair loss and regrowth, and homozygous fetuses die at bi

89 pattern, with regionally cyclic episodes of hair loss and regrowth, and ultimately progresses to alo

90 Sfn(+/Er) mice are characterized by repeated hair loss and regrowth, whereas Sfn(Er/Er) mice die at b

91 ormalities, including cyclic and progressive hair loss and sebaceous gland hypertrophy.

92 onset excessive grooming with mild-to-severe hair loss and self-injury.

93 The Hr-/- phenotype includes both hair loss and severe wrinkling of the skin.

94 n-promoting molecule, N-WASP, display cyclic hair loss and skin inflammation.

95 pulsive grooming behaviour leading to facial hair loss and skin lesions; both behaviours are alleviat

96 sembly of viral-like particles, resulting in hair loss and stem cell exhaustion that is reversible by

97 so revealed that IR induced HF dystrophy and hair loss and suppressed WNT signaling in a p53- and dos

98 Our model suggests that only when hair loss and sweating ability reach near-modern human l

99 EAA (average disease duration 14 years, 95% hair loss) and six control subjects.

100 striking delays in eyelid opening, wavy fur, hair loss, and epidermal hyperplasia with increased leve

101 cterized by delayed hair growth, progressive hair loss, and excessive accumulation of dermal choleste

102 ion causes sebaceous gland (SG) hypertrophy, hair loss, and extracutaneous abnormalities including gr

103 ficient phenotype, including stunted growth, hair loss, and iron-deficient erythropoiesis.

104 nd patch of hair loss to full scalp and body hair loss, and is associated with atopic, autoimmune and

105 e identified with obstructed airways, cyclic hair loss, and severe immunodeficiency subsequent to the

106 The disease was characterized by erythema, hair loss, and the development of scales and crusts.

107 ic alopecia (AGA) is the most common type of hair loss, and there is a lack of ideal treatment option

108 erse events of loss of taste, muscle cramps, hair loss, and weight loss.

109 N) mice differ from other Hr mutants in that hair loss appears as the postnatal coat begins to emerge

110 well as the presence of eyelash and eyebrow hair loss are also impactful and should be considered in

111 isms controlling human hair growth and scalp hair loss are poorly understood.

112 This dermatitis is accompanied by localized hair loss associated with formation of utriculi and derm

113 is a common cause of non-scaring autoimmune hair loss, associated with substantial psychosocial burd

114 vs no scalp cooling was associated with less hair loss at 4 weeks after the last dose of chemotherapy

115 , poor hair anchoring ability, and premature hair loss at early telogen phase of the hair cycle, resu

116 ounds in a neonatal rat model of CIA reduced hair loss at the site of application in 33 to 50% of the

117 Runted mice showed hair loss at weaning.

118 Specifically, we postulate progressive hair loss being selected and this allowing individuals t

119 adverse events and/or ineffectiveness, with hair loss being the most common adverse event leading to

120 n elevated levels of RA in skin and cyclical hair loss; both are prevented by dietary retinol depriva

121 may be safe and effective for patients with hair loss, but larger trials and standardized guidelines

122 fter birth and gradually led to nearly total hair loss by 8 mo.

123 Hair loss can be a psychologically devastating adverse e

124 simplex is a rare autosomal dominant form of hair loss characterized by hair follicle miniaturization

125 atrichia is a rare form of hereditary human hair loss, characterized by the complete shedding of hai

126 We found in the SAM P(8) strain that hair loss, coarseness of hair texture, and ulceration of

127 1) greater decrease in the surface area with hair loss, compared with the hydrocortisone group at all

128 ew algorithmic quantification system for all hair loss, computational imaging analysis and algorithm

129 is a common heritable and androgen-dependent hair loss condition in men.

130 Hair loss developed by 3 mo after birth and gradually le

131 vels, and hemoglobin levels of women without hair loss differed from the means in each alopecia group

132 used for the treatment of a T cell-mediated hair loss disease (alopezia areata).

133 a areata (AA) is a non-scarring inflammatory hair loss disease with a complex autoimmune etiopathogen

134 Alopecia areata is an inflammatory hair loss disease with a major genetic component.

135 ia areata (AA), the most common inflammatory hair loss disease, at a higher prevalence than the gener

136 Alopecia areata is a suspected autoimmune hair loss disease.

137 normal hair growth, the basis of hereditary hair loss diseases, and the origin of follicle-based tum

138 -resistant rickets have a similar congenital hair loss disorder caused by mutations in hairless (HR)

139 Alopecia areata (AA) is an autoimmune hair loss disorder with no cure.

140 cia areata (AA), a non-scarring inflammatory hair loss disorder, is a complex disease determined by g

141 opecia areata (AA) is a chronic, nonscarring hair-loss disorder associated with significant quality-o

142 This group of permanent hair loss disorders can be classified into distinct subg

143 lian hairless (Hr) gene result in congenital hair loss disorders in both mice and humans, the precise

144 additional undesirable phenotypes, including hair loss, dry eye, leukocytosis, xanthomatosis, and a r

145 he K14-DN-Clim mice also develop progressive hair loss due to dysfunctional hair follicles that fail

146 is a complex genetic disease that results in hair loss due to the autoimmune-mediated attack of the h

147 autoimmune diseases, leading to disfiguring hair loss due to the collapse of immune privilege of the

148 oembolism, seizures, psychotic disorder, and hair loss (each as composite endpoints with death to acc

149 ity regression error, and average percentage hair loss error for labeled images, and Pearson correlat

150 uries and symptoms mimicking SCAR, including hair loss, erythema, increase of inflammatory lymphocyte

151 Hair loss experts with experience treating pediatric pat

152 a that was clearly attributable to the drug, hair loss, extravasation necrosis, or decreases in eject

153 ssion, difficulty in cosmetically concealing hair loss, facial hair involvement (eyebrows, eyelashes,

154 e assigned cream twice daily to the areas of hair loss for 2 cycles of 6 weeks on, 6 weeks off, for a

155 , 1 with scalp hair loss and 1 with complete hair loss, for a total of 18 images.

156 fective and safe for treating female pattern hair loss (FPHL)?

157 Genotoxicity-induced hair loss from chemotherapy and radiotherapy is often en

158 epair can be a potential approach to prevent hair loss from chemotherapy and radiotherapy.

159 ormal group consisted of 11 subjects without hair loss from the same referral base and source populat

160 acterized by androgen-dependent, progressive hair loss from the scalp.

161 were off voriconazole for at least 3 months, hair loss had stopped in 94 (82%) and regrowth had begun

162 Stimulation of hair growth in hair loss has been a difficult goal to achieve.

163 Although hair loss has been reported in association with heredita

164 ysis of preoperative risk factors found body hair loss (hazard ratio, 17.3; P > 0.005), preoperative

165 nocyte responses during chemotherapy-induced hair loss, however, remain largely unknown.

166 w growth retardation, cyclic and progressive hair loss, hyperplastic epidermis, abnormal hair follicl

167 The histologic changes associated with the hair loss, i.e., peri-, and intrafollicular inflammatory

168 3tm1stan mice develop phenotypic runting and hair loss, identical to that of the mouse mutant, Dsg3ba

169 se events were observed in any group, except hair loss in 1 patient, which led to discontinuation of

170 inflammatory reaction resulting in complete hair loss in 67% of the grafts by 10 weeks.

171 17 gene (mK17) causes severe but reversible hair loss in a strain-dependent fashion in mouse.

172 ASCs can accelerate wound-healing and reduce hair loss in acid-burn skin injury.

173 ile KCNJ2-mediated hyperpolarization rescues hair loss in aging and androgenetic alopecia models.

174 Alopecia areata (AA)-like hair loss in C3H/HeJ mice provides an excellent model fo

175 t coat-hair whitening, which preceded patchy hair loss in depigmented areas.

176 In this study we examine the mechanism of hair loss in GsdmA3(Dfl)/+ mice.

177 grafts from AA-affected C3H/HeJ mice induced hair loss in histocompatible C3H/OuJ mice (four of 13) a

178 ic alopecia (mpAGA), the most common form of hair loss in men, represents a heritable, androgen-depen

179 ause papular atrichia in humans and complete hair loss in mice and other mammals.

180 Alopecia areata (AA) is characterized by hair loss in patches and may progress to total loss of s

181 postmitotic follicular keratinocytes drives hair loss in patients with Olmsted syndrome.

182 DFMO treatment-associated hair loss in PKC epsilon transgenic mice was accompanied

183 However, DFMO treatment led to marked hair loss in PKC epsilon transgenic mice.

184 c beta cells; wound healing and irreversible hair loss in the skin; and permanent moderate deafness d

185 Hair loss in these mice is similar to that seen in prima

186 lecular phenotypes to identify the basis for hair loss in this model.

187 niaturization of hair follicles and eventual hair loss in wild-type mice and in humans.

188 ame doses of gamma-radiation caused dramatic hair loss in wild-type mice when administered in the mor

189 ated scarring, disfigurement, and persistent hair loss, in addition to their long-term impact on psyc

190 alopecia areata (AA), an autoimmune form of hair loss, in small, uncontrolled studies and case repor

191 Then, as our ancestors' hair loss increased and sweating ability improved over e

192 ace, education, and marital status, survivor hair loss increased risk of anxiety (RR, 1.60; 95% CI, 1

193 py for inhibiting keratinocyte apoptosis and hair loss induced by chemotherapy.

194 f GVHD, as measured by profound weight loss, hair loss, inflammation of foot pads and ears, and profo

195 Hair loss is a distressing side-effect of cancer therapy

196 Our analysis suggests that patterned hair loss is associated with a higher risk of fatal pros

197 Hair loss is associated with a progressive dilatation of

198 ep hair phenomics shows that the progressive hair loss is associated with a switch of hair-type propo

199 l numbers fluctuate over the hair cycle, and hair loss is associated with gradual depletion/atrophy o

200 human in vivo model for chemotherapy-induced hair loss is closer to clinical reality than to any earl

201 ommon, but may be distressing, especially if hair loss is extensive.

202 itotic peak, compared with the evening, when hair loss is minimal.

203 Chemotherapy-induced hair loss is one of the most devastating side effects of

204 rity is often defined by the degree of scalp hair loss, its impact on QOL can also be a defining meas

205 There are several forms of hereditary human hair loss, known collectively as alopecias, the molecula

206 ularity, fast food consumption, pimples, and hair loss, levels.

207 Because hair loss may be a surrogate measure of androgenic activ

208 wn that an algorithm quantitating percentage hair loss may be applied to all forms of alopecia.

209 onscarring alopecia (n = 39), female pattern hair loss (n = 55), or male pattern hair loss (n = 6).

210 pattern hair loss (n = 55), or male pattern hair loss (n = 6).

211 Significantly more episodes of drowsiness, hair loss, nausea, and dry or itchy scalp were reported

212 d-type mice, p53-deficient mice show neither hair loss nor apoptosis in the HF keratinocytes that mai

213 ale (grade 0 [no hair loss] or grade 1 [<50% hair loss not requiring a wig] were considered to have h

214 Severe hair loss observed in PKC epsilon transgenic mice on DFM

215 rly androgenetic alopecia (AGA) is patterned hair loss occurring before age 30 years.

216 Hair loss of 50% or less (Dean score of 0-2) was seen in

217 iation and cycling, leading to a progressive hair loss of mutant (MT) mice.

218 areata (AA) is characterized by nonscarring hair loss of the scalp, face, and/or body.

219 disease of the hair follicle that results in hair loss of varying severity.

220 The impact of disfigurement and hair loss on HRQOL (ie, Medical Outcomes Short Form-36)

221 f severity that ranges from patchy localized hair loss on the scalp to the complete absence of hair e

222 Hair loss on the scalp was noted in 120 (96%), arms and

223 95% CI 2.12-13.96) and those who experienced hair loss (OR = 6.94, 95% CI 1.03-46.92), headache (OR =

224 size without causing leukocytosis, dry eye, hair loss, or a reduced life span.

225 Hair loss, or alopecia, may occur as a primary skin diso

226 dverse Events version 4.0 scale (grade 0 [no hair loss] or grade 1 [<50% hair loss not requiring a wi

227 cent, typically characterized by progressive hair loss originating at the vertex of the scalp.

228 me was the change in scalp surface area with hair loss over 24 weeks following enrollment.

229 ommon form of alopecia areata (AA) involving hair loss over the entire scalp and body and is often di

230 understanding the genetic etiology of human hair loss over the previous decade, there remain a numbe

231 at the start of follow-up and recalled their hair-loss patterns at age 45 years.

232 The runting and hair loss phenotype of DSG3 -/- mice is identical to tha

233 Defolliculated (Gsdma3(Dfl)/+) mice have a hair loss phenotype that involves an aberrant hair cycle

234 Surprisingly, K5.CtBP1 pups also exhibited a hair loss phenotype.

235 in, and increased Zipro1 dosage results in a hair-loss phenotype associated with increased epithelial

236 d (Dfl) is a spontaneous mouse mutant with a hair-loss phenotype that includes altered sebaceous glan

237 Although the degree of scalp hair loss (physician Severity of Alopecia Tool score) wa

238 llicular lichen planus, causing irreversible hair loss predominantly in postmenopausal individuals.

239 pathological skin conditions (stress-induced hair loss, psoriasis, atopic dermatitis).

240 Alopecia areata (AA) is characterized by hair loss ranging from patches of hair loss to more exte

241 The etiology of hair loss remains enigmatic, and current remedies remain

242 The mechanism underlying the hair loss remains unclear.

243 in size, with eyelid irritation and sporadic hair loss resembling the cyclical alopecia observed in m

244 rement (RR, 1.19; 95% CI, 1.05 to 1.35), and hair loss (RR, 1.26; 95% CI, 1.09 to 1.47).

245 e risk [RR], 2.42; 95% CI, 2.22 to 2.65) and hair loss (RR, 4.24; 95% CI, 3.63 to 4.95).

246 ed outcome for eyebrow hair loss and eyelash hair loss scores of 0 or 1 (full coverage or minimal gap

247 the key features of the chemotherapy-induced hair loss seen in patients with cancer and (ii) this hum

248 iation with HRQOL included higher self-rated hair loss severity, lower visual analog scale score, and

249 lso have marked glutathione (GSH) depletion, hair loss, skin erosion, gut mucosal atrophy, and deplet

250 mice showed unkempt and greasy hair coat and hair loss soon after birth.

251 A total of 43 hair loss specialist dermatologists from 12 countries pa

252 Msx2-deficient mice exhibit progressive hair loss, starting at P14 and followed by successive cy

253 ssor provides a molecular basis for specific hair loss syndromes in both humans and mice.

254 owledge of specific mechanisms through which hair loss takes place under pathological situations is n

255 e alopecia mutation (jal) display patches of hair loss that appear as soon as hair develops in the ne

256 c disease flares characterized by increasing hair loss that follow a seasonal pattern.

257 splay an aging phenotype of hair graying and hair loss that is attributed to impaired HF ESC mobiliza

258 After adjusting for baseline hair loss, the clobetasol group had a statistically sign

259 optosis in the hair follicles (HF) and cause hair loss, the most common side effect of chemotherapy.

260 ments and dietary interventions for treating hair loss, the safety and effectiveness of available pro

261 The present results for hair loss therapy are discussed.

262 row hair-are miniaturized by ageing to cause hair loss through the depletion of hair follicle stem ce

263 features, from a single small round patch of hair loss to full scalp and body hair loss, and is assoc

264 terized by hair loss ranging from patches of hair loss to more extensive forms, including alopecia to

265 Self-estimated hair loss using the Dean scale was assessed 4 weeks afte

266 il onset and the extent and reversibility of hair loss, varied widely.

267 The hair loss was associated with premature differentiation

268 Hair loss was more prevalent than described before, warr

269 Conversely, patterned hair loss was not statistically significantly associated

270 Hair loss was reported by 2.9% (n = 53/1859) of patients

271 t profile, and use of LDOM for patients with hair loss was reviewed.

272 owever, the thermoregulatory explanation for hair loss was supported.

273 A Dean scale score of 0 to 2 (</=50% hair loss) was defined as treatment success.

274 In a mouse model for chemotherapy-induced hair loss, we demonstrate that p53 is essential for this

275 ecia, additional questions about reversal of hair loss were asked after voriconazole had been stopped

276 Portrait images of 6 individuals without hair loss were created using artificial intelligence and

277 ported scarring/disfigurement and persistent hair loss were examined in 14,358 survivors and 4,023 si

278 ny oral medication or hormonal treatment for hair loss were excluded from the study.

279 diac hypertrophy, leukopenia, and weight and hair loss were not detected with CuDox-LTSLs after the 2

280 with alopecia areata and at least 50% scalp hair loss were randomly assigned to oral ritlecitinib or

281 irty-two age-matched men with no evidence of hair loss were recruited as controls.

282 ged 19 to 30 years presenting with patterned hair loss were recruited as study participants.

283 , 355 men aged 40-60 years with male-pattern hair loss were stratified by age decade (40-49 years and

284 ownregulated Shh gene expression and induced hair loss, whereas doxorubicin or Ara-C did not.

285 m 6 weeks of age, mice underwent progressive hair loss which correlated with the development of derma

286 reased risk for disfigurement and persistent hair loss, which is associated with future emotional dis

287 Adult Dgat(-/-) mice had dry fur and hair loss, which were associated with atrophic sebaceous

288 cia areata (AA) is an autoimmune disorder of hair loss with a complex and evolving treatment landscap

289 Alopecia areata is an idiopathic cause of hair loss with limited therapeutic repertoire.

290 ed the association of dermatologist-assessed hair loss with prostate cancer-specific mortality in the

291 rong correlations with underlying percentage hair loss, with coefficient of determination R2 values o

292 ity and 5 indicates the most severe stage of hair loss, with little or no hair in the centroparietal

293 g dystrophic follicular cysts formation with hair loss, with potential connections to pathogenic proc

294 the list of genes with effects on behavioral hair loss, with the added twist that this time the gene

295 ausea, vomiting, constipation, diarrhea, and hair loss) within three randomized trials.

296 nterventions in individuals with alopecia or hair loss without a known baseline nutritional deficienc

297 on between scalp cooling and reduced risk of hair loss would be demonstrated if 50% or more of patien

298 A generalizable automated assessment of hair loss would provide a way to standardize measurement

299 or tissue engineering and new treatments for hair loss, wound healing and other degenerative skin dis

300 "dystrophic catagen" initially enhanced the hair loss, yet subsequently promoted accelerated hair fo